NCT04557306View on ClinicalTrials.gov

Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions
Solid Tumor
Interventions
BIOLOGICAL

CBT101 cells, every 2 weeks

CBT101 cells, every 4 weeks

BIOLOGICAL

CBT101 cells, every 4 weeks

CBT101 cells, every 4 weeks

Trial Locations (1)

13496

CHA Bundang Medical Center, Seongnam-si

All Listed Sponsors
lead

CHABiotech CO., Ltd

INDUSTRY

NCT04557306 - Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer | Biotech Hunter | Biotech Hunter